Musculoskeletal Involvement

  • Guillermo J. Pons-Estel
  • Bernardo A. Pons-Estel
  • Graciela S. Alarcón


Musculoskeletal manifestations such as myalgias, arthralgias, an intermittent non-erosive mild polyarthritis affecting mainly small joints, are common in patients with primary Sjögren’s syndrome. Myositis may also occur but much less frequently. The most important features of these manifestations are described in this chapter.


Rheumatoid Arthritis Inclusion Body Myositis Inflammatory Myopathy Articular Involvement Musculoskeletal Manifestation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pertovaara M, Pukkala E, Laippala P, et al. A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001;60:467–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Ioannidis J, Vassiliou V, Moutsopoulos H. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46:741–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Theander E, Manthorpe R, Jacobsson L. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum. 2004;50:1262–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, et al. Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford). 2006;45:187–91.CrossRefGoogle Scholar
  5. 5.
    Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210–9.CrossRefGoogle Scholar
  6. 6.
    Haga HJ, Peen E. A study of the arthritis pattern in primary Sjögren’s syndrome. Clin Exp Rheumatol. 2007;25:88–91.PubMedGoogle Scholar
  7. 7.
    Kruize AA, Hené RJ, Van Der Heide A, et al. Long-term followup of patients with Sjögren’s syndrome. Arthritis Rheum. 1996;39:297–303.PubMedCrossRefGoogle Scholar
  8. 8.
    Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol. 1999;28:227–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Ramos-Casals M, Cervera R, Font J, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus. 1998;7:202–6.PubMedCrossRefGoogle Scholar
  10. 10.
    García-Carrasco M, Cervera R, Rosas J, et al. Primary Sjögren’s syndrome in the elderly: clinical and immunological characteristics. Lupus. 1999;8:20–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Barrs DM, McDonald TJ, Duffy J. Sjögren’s syndrome involving the larynx: report of a case. J Laryngol Otol. 1979;93:933–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Sève P, Poupart M, Bui-Xuan C, et al. Cricoarytenoid arthritis in Sjögren’s syndrome. Rheumatol Int. 2005;25:301–2.PubMedCrossRefGoogle Scholar
  13. 13.
    García-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81:270–80.CrossRefGoogle Scholar
  14. 14.
    Kamali S, Polat NG, Kasapoglu E, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol. 2005;24:673–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther. 2008;10:1–6.CrossRefGoogle Scholar
  16. 16.
    Papiris SA, Tsonis IA, Moutsopoulos HM. Sjögren’s syndrome. Semin Respir Crit Care Med. 2007;28:459–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Rehman HU. Sjögren’s syndrome. Yonsei Med J. 2003;44:947–54.PubMedGoogle Scholar
  18. 18.
    Castro-Poltronieri A, Alarcón-Segovia D. Articular manifestations of primary Sjögren’s syndrome. J Rheumatol. 1983;10:485–8.PubMedGoogle Scholar
  19. 19.
    Rantapaa-Dahlqvist SR, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptides and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Gottenberg JE, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64:114–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Goëb V, Salle V, Duhaut P, et al. Clinical significance of autoantibodies recognizing Sjögren’s syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren’s syndrome. Clin Exp Immunol. 2007;148:281–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus erythematosus. Medicine (Baltimore). 1993;72:113–24.Google Scholar
  23. 23.
    Spilberg I, Siltzbach LE, McEwen C. The arthritis of sarcoidosis. Arthritis Rheum. 1969;12:126–37.PubMedCrossRefGoogle Scholar
  24. 24.
    Petri MA. In: Koopman WJ, editor. Arthritis and allied conditions – a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkin; 2001. p. 1455–79.Google Scholar
  25. 25.
    Martinez-Lavin M, Vaughan JH, Tan EM. Autoantibodies and the spectrum of Sjögren’s syndrome. Ann Intern Med. 1979;91:185–90.PubMedGoogle Scholar
  26. 26.
    Vitali C, Tavoni A, Neri R, et al. Fibromyalgia features in patients with primary Sjögren’s syndrome. Evidence of a relationship with psychological depression. Scand J Rheumatol. 1989;18:21–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Tishler M, Barak Y, Paran D, et al. Sleep disturbances, fibromyalgia and primary Sjögren’s syndrome. Clin Exp Rheumatol. 1997;15:71–4.PubMedGoogle Scholar
  28. 28.
    Lindvall B, Bengtsson A, Ernerudh J, et al. Subclinical myositis is common in primary Sjögren’s syndrome and is not related to muscle pain. J Rheumatol. 2002;29:717–25.PubMedGoogle Scholar
  29. 29.
    Alexander EL. Neuromuscular complications of primary Sjögren’s syndrome. In: Talal N, Moutsopoulos HM, Kassan SS, editors. Sjögren’s syndrome. Clinical and immunological aspects. Berlin: Springer; 1987. p. 61–82.Google Scholar
  30. 30.
    Chad D, Good P, Adelman L, et al. Inclusion body myositis associated with Sjögren’s syndrome. Arch Neurol. 1982;39:186–8.PubMedGoogle Scholar
  31. 31.
    Gutmann L, Govindan S, Riggs JE, et al. Inclusion body myositis and Sjögren’s syndrome. Arch Neurol. 1985;42:1021–2.PubMedGoogle Scholar
  32. 32.
    Khraishi MM, Jay V, Keystone EC. Inclusion body myositis in association with vitamin B12 deficiency and Sjögren’s syndrome. J Rheumatol. 1992;19:306–9.PubMedGoogle Scholar
  33. 33.
    Vrethem M, Lindvall B, Holmgren H, et al. Neuropathy and myopathy in primary Sjögren’s syndrome: neurophysiological, immunological and muscle biopsy results. Acta Neurol Scand. 1990;82:126–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Kraus A, Cifuentes M, Villa AR, et al. Myositis in primary Sjögren’s syndrome. Report of 3 cases. J Rheumatol. 1994;21:649–53.PubMedGoogle Scholar
  35. 35.
    Molina R, Provost TT, Arnett FC, et al. Primary Sjögren’s syndrome in men. Clinical, serologic, and immunogenetic features. Am J Med. 1986;80:23–31.PubMedCrossRefGoogle Scholar
  36. 36.
    Ringel SP, Forstot JZ, Tan EM, et al. Sjögren’s syndrome and polymyositis or dermatomyositis. Arch Neurol. 1982;39:157–63.PubMedGoogle Scholar
  37. 37.
    Layzer RB. Inflammatory and immune disorders. In: Layzer RB, editor. Neuromuscular manifestations of systemic disease. Philadelphia: Davis; 1985. p. 227–8.Google Scholar
  38. 38.
    Leroy JP, Drosos AA, Yiannopoulos DI, et al. Intravenous pulse cyclophosphamide therapy in myositis and Sjögren’s syndrome. Arthritis Rheum. 1990;33:1579–81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Guillermo J. Pons-Estel
    • 1
    • 2
  • Bernardo A. Pons-Estel
    • 3
  • Graciela S. Alarcón
    • 2
  1. 1.Department of Autoimmune DiseasesInstitut Clínic de Medicina i Dermatologia, Hospital ClínicBarcelona, CataloniaSpain
  2. 2.Division of Clinical Immunology and Rheumatology, Department of Medicine, School of MedicineThe University of Alabama at BirminghamBirminghamUSA
  3. 3.Department of RheumatologyInstituto Cardiovascular de RosarioRosarioArgentina

Personalised recommendations